AIs are used in postmenopausal women whose source
of estrogen is adipose tissue and adrenal glands. The
AIs suppress the estrogen synthesis and quantity by rerepressing
the aromatase enzyme. Included in this group
are the nonsteroidal AIs, anastrozole and letrozole, and
the steroidal AIs, such as exemestane (Harwood, 2004;
Hassey-Dow, 2002). LHRH agonists suppress ovarian
hormonal activity. This group is prescribed to premenopausal
women (Hallquist-Viale, 2005; McGinn & Moore,
2001). Preparations in this group include goserelin and
leuprorelin.